abrdn Life Sciences Investors
HQL
69 hedge funds and large institutions have $65.2M invested in abrdn Life Sciences Investors in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 30 increasing their positions, 16 reducing their positions, and 10 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 16
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
1.18% more ownership
Funds ownership: 17.94% → 19.12% (+1.2%)
0% more funds holding
Funds holding: 69 → 69 (0)
8% less capital invested
Capital invested by funds: $71.2M → $65.2M (-$5.97M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
Top Sellers
HQL Hedge Fund Activity: Q1 2020 in Review
69 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q1 2020, worth a combined $65.2M — down 8.4% from $71.2M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new HQL positions and 10 closed out — a net gain of 2 holders — while 30 added to existing stakes and 16 trimmed.
The largest buyer was Matisse Capital, opening a new position worth an estimated $3.18M. The largest seller was Cornerstone Advisors, exiting entirely with an estimated $3.05M sold.
- 69 institutional investors held abrdn Life Sciences Investors (HQL) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $65.2M of abrdn Life Sciences Investors stock for Q1 2020, down 8.4% quarter-over-quarter.
- 12 funds opened new abrdn Life Sciences Investors positions in Q1 2020 and 10 closed out, a net change of +2 holders.
- The largest abrdn Life Sciences Investors buyer in Q1 2020 was Matisse Capital, an estimated $3.18M added.
- The largest abrdn Life Sciences Investors seller in Q1 2020 was Cornerstone Advisors, an estimated $3.05M sold.
Based on aggregated 13F filings for Q1 2020.